CDK4/6 inhibitorPhase 3 trialInvestigational
Abemaciclib
How it works
Blocks the CDK4 and CDK6 enzymes, preventing cell division and growth.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
Studies show that abemaciclib can improve progression-free survival in HR-positive patients with advanced breast cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| MicroRNA Helps Cancer Cells Respond to Treatment | Breast Cancer | lab-study | — | Source → |
| Testing Abemaciclib Before a New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Abemaciclib Rechallenge Shows Promise in Metastatic Breast Cancer | Breast Cancer | phase-2 | The median progression-free survival was 4.2 months, with 7.1 months in patients who switched from abemaciclib plus AI/TAM to abemaciclib plus FUL. | Source → |
| Abemaciclib for Recurrent Ovarian or Endometrial Cancer Treatment | Ovarian Cancer | phase-2 | — | Source → |
| Abemaciclib Dose Escalation Trial for Breast Cancer | Breast Cancer | preclinical | — | Source → |
| Testing New Combination Therapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Abemaciclib Dose Escalation Study in Early Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Evaluating Probiotics for Abemaciclib-Related Abdominal Discomfort | Breast Cancer | phase-2 | — | Source → |
| Testing Abemaciclib and Hydroxychloroquine for Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Abemaciclib and Endocrine Therapy for Older Patients with Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Abemaciclib and Letrozole in Rare Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Breast Cancer Treatment Trial Examines Abemaciclib and Endocrine Therapy | Breast Cancer | phase-3 | — | Source → |
| Evaluating Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing Combination of Anti-cancer Drugs for Rare Cancers | Breast Cancer | phase-1 | — | Source → |
| Testing Abemaciclib with Chemotherapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing New Treatments for Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Breast Cancer Treatment Study | Breast Cancer | preclinical | — | Source → |
| Testing Chemotherapy vs Hormone Therapy with Abemaciclib in Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Abemaciclib Fails to Meet Primary Endpoint in Brain Metastases Study | Lung Cancer | phase-2 | A volumetric decrease in target intracranial lesions was 22.7% for NSCLC and 18.8% for melanoma cohorts. | Source → |
| Combining Ferulic Acid with Breast Cancer Drugs May Improve Treatment | Breast Cancer | lab-study | — | Source → |
| Abemaciclib May Cause Skin Reactions in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| New Combination Therapy Tested for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Combination Therapy Shows Promise in Rare Male Breast Cancer | Breast Cancer | observational | — | Source → |
| Managing Diarrhea in Breast Cancer Patients with Abemaciclib | Breast Cancer | observational | Severe (G3) diarrhea was significantly less frequent in the Postbio group (0%) compared to the Standard one (7.9%; P = .029). | Source → |
| Abemaciclib Shows Promise in Treating Advanced Prostate Cancer | Prostate Cancer | phase-2 | The objective response rate without concurrent bone progression was 6.8%. | Source → |
| Abemaciclib Improves Survival in High-Risk Early Breast Cancer | Breast Cancer | phase-3 | Abemaciclib plus endocrine therapy demonstrated a statistically significant improvement in invasive disease-free survival, with an absolute improvement of 3.5% at 2 years. | Source → |
| Researchers Treat Breast Cancer with Letrozole and Abemaciclib | Breast Cancer | observational | — | Source → |
| Abemaciclib with Endocrine Therapy for Early Breast Cancer | Breast Cancer | phase-3 | Trial results showed improvements in invasive disease-free survival for the abemaciclib arm. | Source → |
| New Treatment Option for High-Risk Breast Cancer | Breast Cancer | phase-3 | Abemaciclib plus endocrine therapy reduced the risk of recurrence of breast cancer compared with endocrine therapy alone. | Source → |
| Abemaciclib Therapy Linked to Higher Risk of Blood Clots in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Continuing CDK Inhibitors After Disease Progression in ER-positive Breast Cancer | Breast Cancer | observational | The overall response rate was 16.0% and the clinical benefit rate was 44.0%. | Source → |
| Abemaciclib Improves Disease-Free Survival in High-Risk Breast Cancer | Breast Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.